Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binds in the S(1)(') pocket of the enzyme
通过使用计算模型,基于通过文件筛选确定的先导
抑制剂,设计了一系列基于
嘧啶三酮的MMP-13
抑制剂。在
嘧啶三酮环的C-5位置掺入联芳基醚部分导致MMP-13效力显着提高。蛋白质晶体学揭示该部分结合在酶的S(1)(')口袋中。末端芳族环的C-4取代基的优化导致相对于MMP-14(
MT-1 MMP)的选择性的结合。满足我们体外效价和选择性目标的化合物的药代动力学数据显示了联芳醚取代基的结构活性关系。